German chemical and pharmaceutical major Bayer (NASDAQOTH:BAYRY) is raising the stakes in its months-long bid to acquire American peer Monsanto (NYSE:MON). Bayer has improved its offer to $127.50 per share, upping its previous bid by $2.50.
The European company stipulated that it would pay that amount, which values Monsanto at more than $65 billion with debt included "only in connection with a negotiated transaction."
In acknowledging the new offer, Monsanto said it has been "engaged in constructive negotiations" with its would-be acquirer. It added that it is "continuing these conversations as it evaluates this proposal, as well as proposals from other parties and other strategic alternatives." It did not elaborate.
This is Bayer's third offer since it launched its takeover effort this past May with a $122-per-share bid.
Does it matter?
Monsanto is clearly warming to the idea of being swallowed by Bayer, as indicated by the optimistic language of its response. Investors, however, seem much more skeptical regarding the possibility of a deal. Since the latest offer was made public, the stock hasn't moved much above $108 per share.
That might be because a potential tie-up between the two companies would face a great deal of regulatory scrutiny, particularly in Europe, which might be tough to surmount as Europeans have been very resistant to Monsanto's efforts in the sphere of genetically modified food.
That said, consolidation is in the air in the "big agribusiness" segment. Last month, Syngenta's potential acquisition by ChemChina got a crucial green light from the Committee on Foreign Investment in the U.S. In 2015, Syngenta was the target of an ultimately abandoned takeover attempt by none other than Monsanto.
Although Bayer and Monsanto seem to be tilting toward a deal, if one is reached, it would be only the start of a long, protracted process -- most likely involving significant compromises with concerned regulators. However this story ends, it won't end quickly.
Eric Volkman has no position in any stocks mentioned. Nor does the Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Growth Stocks With Virtual Monopolies
Invest in companies with overwhelming dominance in their industries.
Monsanto Finishes Fiscal 2017 Strong Even as Merger Doubts Linger
The agricultural giant continues to work hard with its seed and genomics work.
5 Incredible Synthetic Biology Holy Grails That Could Change the World
Investors are still waiting for next-generation biotech to deliver on its enormous promise and potential, but just one of these Holy Grails would make the wait worth it.